Cholesterol drug could boost cancer therapy in patients with specific gene mutation
NCT ID NCT07213557
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding the common cholesterol drug simvastatin to standard chemotherapy and immunotherapy (nivolumab) can help people with a specific genetic mutation (ARID1A) in advanced stomach or esophageal cancer. About 84 participants will receive either the combination or standard treatment alone. The main goal is to see if more patients are alive without their cancer growing after one year.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- simvastatin (a cholesterol-lowering drug) added to nivolumab and oxaliplatin-based chemotherapy
- What this could lead to
- If it works, this could point toward a more effective first-line treatment for people with this specific genetic subtype of advanced gastroesophageal cancer.
- What could go wrong
- This is a small, early-phase trial (84 participants) testing a drug not originally designed for cancer. The benefit may be modest or absent, and side effects from the combination are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC GASTROOESOPHAGEAL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Istituto Nazionale Tumori Fondazione G. Pascale
RECRUITINGNaples, Italia, 80131, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••